(Q53971184)

23 May 2018

title

Prospective, open-label, add-on study of lamotrigine in 56 children with intractable generalized epilepsy. (English)

1 reference

23 May 2018

1 reference

2

1 reference

23 May 2018

author name string

K Farrell

1

1 reference

23 May 2018

R Munn

3

1 reference

23 May 2018

S Peng

4

1 reference

23 May 2018

L M MacWilliam

5

1 reference

23 May 2018

publication date

1 April 1997

1 reference

23 May 2018

published in

Pediatric Neurology

1 reference

23 May 2018

volume

16

1 reference

23 May 2018

issue

3

1 reference

23 May 2018

page(s)

201-205

1 reference

23 May 2018

Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2897%2900010-6

7 January 2021

Controlled trial of lamotrigine (Lamictal) for refractory partial seizures

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2897%2900010-6

7 January 2021

A randomised double-blind placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2897%2900010-6

7 January 2021

Double-blind, placebo controlled, crossover study of lamotrigine in treatment resistant partial seizures

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2897%2900010-6

7 January 2021

Outcomes of add-on treatment with lamotrigine in partial epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2897%2900010-6

7 January 2021

Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2897%2900010-6

7 January 2021

Acute effects of lamotrigine (BW430C) in persons with epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2897%2900010-6

7 January 2021

Lamotrigine in primary generalised epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2897%2900010-6

7 January 2021

Lamotrigine as an add-on drug in the management of Lennox-Gastaut syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2897%2900010-6

7 January 2021

Lamotrigine in resistant childhood epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2897%2900010-6

7 January 2021

Epilepsy with myoclonic absences

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2897%2900010-6

7 January 2021

Lamotrigine in treatment of 120 children with epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2897%2900010-6

7 January 2021

Lamotrigine for the treatment of epilepsy in childhood

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2897%2900010-6

7 January 2021

Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2897%2900010-6

7 January 2021

Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2897%2900010-6

7 January 2021

Lamotrigine in infantile spasms

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2897%2900010-6

7 January 2021

Epilepsy with myoclonic absences

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2897%2900010-6

7 January 2021

Lamotrigine for generalised epilepsies

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2897%2900010-6

7 January 2021

Safety of lamotrigine

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2897%2900010-6

7 January 2021

Sodium valproate acutely inhibits lamotrigine metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2897%2900010-6

7 January 2021

Serum anticonvulsant concentrations and the risk of drug induced skin eruptions

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2897%2900010-6

7 January 2021

Rechallenge with lamotrigine after initial rash

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2897%2900010-6

7 January 2021

10.1016/S0887-8994(97)00010-6

Identifiers

DOI

1 reference

23 May 2018

PubMed ID

9165509

1 reference

23 May 2018